xGenetic analysis systems developer Agena Bioscience has launched targeted research panels UltraSEEK and iPLEX HS, for the detection of somatic mutations from lung and colon cancers.

The UltraSEEK lung and colon panels can detect mutations as low as 0.1% minor allele frequency (MAF) from circulating tumour cells (CTCs) and circulating tumour DNA (ctDNA), while iPLEX HS can detect mutations as low as 1% MAF from solid tumour tissue.

The panels are designed to complement the firm's MassARRAY system which detects mutations as low as 0.1% MAF from minimal input DNA.

"The low-limit detection capacity of the panels facilitates mutation profiling of ctDNA and CTCs from plasma, as well as solid tumour tissue."

The low-limit detection capacity of the panels facilitates mutation profiling of ctDNA and CTCs from plasma, as well as solid tumour tissue.

The multiplexed panels can work with DNA extracted from a single, 10mL blood draw and target mutations of known significance in BRAF, EGFR, ERBB2, KRAS, NRAS and PIK3CA genes.

In collaboration with the Medical Foundation, a clinical research study was conducted using the iPLEX HS lung panel, SCLC solid tumour samples and a limit of detection of 1% MAF.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The results showed about 10% increase in the number of clinically significant mutations detected compared to other methods with a 5-10% MAF.

The results were found to be consistent in case of colorectal adenocarcinoma samples, where an increase of approximately 6% in the number of mutations detected, was demonstrated.

The panels provide cost-effective mutational profiling across various sample types such as liquid biopsies, and are suitable for laboratories translating discoveries from clinical research to higher throughput testing.